Abstract
Difficulties in the diagnosis and management of patients with Crohn's disease (CD), requiring frequent endoscopic examination due to the lack of a clear correlation between clinical manifestations and endoscopic activity, dictate the need to improve old approaches and search for new ones. Traditionally, markers of the disease are C-reactive protein (CRP) and fecal calprotectin (FC), which also may not always reflect the course of the disease. In our study, we analyzed the role of CRP and FC and considered trimethylamine-N-oxide (TMAO), a breakdown product of choline, phosphatidylcholine, and carnitine formed by the gut microbiome, as a novel biomarker. 85 respondents (47 with BC, 38 healthy individuals) were measured for CRP, FC, and TMAO. It was found that patients with BC had significant differences in the form of increased SRB (p=0.003), FA (p<0.001), and decreased TMAO (p<0.001) in contrast to healthy individuals. CRP and FC correlated with disease activity by clinical, laboratory, and endoscopic activity.